RE:RE:RE:Tidbits from today's presentationYa float, I'm thinking the same. was extremely glad to read our burn rate at 250 per month, that was very positive, more than I think others realize. Well done Roger, that's what I wanted to see over the past 6 months ! Now the cash in the bank looks solid. Other 2 indications are not going to be rushed forward, as that would pull on the existing cash which is supposed to be directed at NMIBC, although I was hoping for a GBM phase1b sooner.
floatinketucky wrote: With our phase 2 under-dosing optimized and illistration of our CR based on the scientific results, it is not going to matter. We will still dominate the data points and the safety profile. Our data points dominated with under-dosed patients and will continue to dominate with properly dosed patients. Its also looks like PH1 patients will be inculuded in the data poits needed for Accelrated approval.
With the current plans for GBM and Lung trials our budget is rock solid. The latest showed 9.7 million to operate on. No PP untill late 2021 and by then we my churn in warrants to extend operation capital out till 2H2022. This is what I was saying about a month ago. I'm still expecting our budget to hold up till spring/summer 2022 and it looks like its still on track.
There is louder radio play on neglecting cancer research.